Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Trinity Biotech (TRIB) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Trinity Biotech (TRIB) over the last 17 years, with Q2 2025 value amounting to $99.6 million.

  • Trinity Biotech's Liabilities and Shareholders Equity rose 559.16% to $99.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $394.7 million, marking a year-over-year increase of 2828.48%. This contributed to the annual value of $103.3 million for FY2024, which is 7378.65% up from last year.
  • According to the latest figures from Q2 2025, Trinity Biotech's Liabilities and Shareholders Equity is $99.6 million, which was up 559.16% from $103.3 million recorded in Q4 2024.
  • Trinity Biotech's 5-year Liabilities and Shareholders Equity high stood at $136.0 million for Q1 2021, and its period low was $59.4 million during Q4 2023.
  • For the 5-year period, Trinity Biotech's Liabilities and Shareholders Equity averaged around $98.6 million, with its median value being $97.9 million (2022).
  • In the last 5 years, Trinity Biotech's Liabilities and Shareholders Equity crashed by 3546.97% in 2023 and then surged by 7378.65% in 2024.
  • Trinity Biotech's Liabilities and Shareholders Equity (Quarter) stood at $118.9 million in 2021, then decreased by 22.53% to $92.1 million in 2022, then tumbled by 35.47% to $59.4 million in 2023, then surged by 73.79% to $103.3 million in 2024, then decreased by 3.54% to $99.6 million in 2025.
  • Its last three reported values are $99.6 million in Q2 2025, $103.3 million for Q4 2024, and $97.4 million during Q3 2024.